Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
Pharmacoeconomics - Open
|
August 21, 2019
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
Peter Wigfield, Urbano Sbarigia, Mahmoud Hashim, et al.
Pharmacoeconomics
|
January 19, 2006
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada
P S Chue, Bart Heeg, Erik Buskens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 7, 2018
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer
Mahmoud Hashim, Boris M Pfeiffer, Robert Bartsch, et al.
Journal of Medical Economics
|
January 19, 2021
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada
Yannan Hu, Majed Charaan, Ilse van Oostrum, et al.
BMC Health Services Research
|
February 20, 2009
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
Maarten Treur, Bart Heeg, Hans-Jürgen Möller, et al.
Journal of Comparative Effectiveness Research
|
September 18, 2020
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients
Urbano Sbarigia, Talitha Vincken, Peter Wigfield, et al.
Scandinavian Journal of Infectious Diseases
|
January 15, 2011
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden
Per-Olof Thuresson, Bart Heeg, Benedicte Lescrauwaet, et al.
Ugeskrift for Laeger
|
September 20, 2006
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]
Bart Heeg, Aukje van Gestel, Ben van Hout, et al.
Journal of Comparative Effectiveness Research
|
December 9, 2025
Simplifying fractional polynomials in Bayesian network meta-analysis via variable powers
Andre Verhoek, Mario Jnm Ouwens, Bart Heeg, et al.
Current Medical Research and Opinion
|
March 18, 2021
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
Bogdan Muresan, Carla Mamolo, Joseph C Cappelleri, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
Pharmacoeconomics - Open
|
August 21, 2019
Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review
Peter Wigfield, Urbano Sbarigia, Mahmoud Hashim, et al.
Pharmacoeconomics
|
January 19, 2006
Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada
P S Chue, Bart Heeg, Erik Buskens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 7, 2018
Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer
Mahmoud Hashim, Boris M Pfeiffer, Robert Bartsch, et al.
Journal of Medical Economics
|
January 19, 2021
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada
Yannan Hu, Majed Charaan, Ilse van Oostrum, et al.
BMC Health Services Research
|
February 20, 2009
A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
Maarten Treur, Bart Heeg, Hans-Jürgen Möller, et al.
Journal of Comparative Effectiveness Research
|
September 18, 2020
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients
Urbano Sbarigia, Talitha Vincken, Peter Wigfield, et al.
Scandinavian Journal of Infectious Diseases
|
January 15, 2011
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden
Per-Olof Thuresson, Bart Heeg, Benedicte Lescrauwaet, et al.
Ugeskrift for Laeger
|
September 20, 2006
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark]
Bart Heeg, Aukje van Gestel, Ben van Hout, et al.
Journal of Comparative Effectiveness Research
|
December 9, 2025
Simplifying fractional polynomials in Bayesian network meta-analysis via variable powers
Andre Verhoek, Mario Jnm Ouwens, Bart Heeg, et al.
Current Medical Research and Opinion
|
March 18, 2021
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia
Bogdan Muresan, Carla Mamolo, Joseph C Cappelleri, et al.
Page
of 5